Showing 1 - 10 of 1,380
Patient mobility is a key issue in the EU who recently passed a new law on patients' right to EU-wide provider choice. In this paper we use a Hotelling model with two regions that differ in technology to study the impact of patient mobility on health care quality, health care financing and...
Persistent link: https://www.econbiz.de/10010229860
Persistent link: https://www.econbiz.de/10012970248
Very few industries are as profoundly influenced by regulation as the pharmaceutical industry. All aspects of the life-cycle of new drugs are regulated, from patent application, to marketing approval, commercial exploitation, patent expiration and competition with generics. The nature of demand...
Persistent link: https://www.econbiz.de/10012980141
During the COVID-19 pandemic, prices for a number of consumer goods and services, as well as for some pharmaceutical and medicines products, have increased significantly. To counter the attempts of unscrupulous sellers to increase their profits by price gouging, the governments of several OECD...
Persistent link: https://www.econbiz.de/10014096077
Patient mobility is a key issue in the EU who recently passed a new law on patients’ right to EU-wide provider choice. In this paper we use a Hotelling model with two regions that differ in technology to study the impact of patient mobility on health care quality, health care financing and...
Persistent link: https://www.econbiz.de/10013315635
In recent years, reverse patent settlement agreements — whereby a patent holder pays or gives other forms of value to an infringer in order to avoid or to settle patent litigation — have raised considerable debate in the pharmaceutical field in both the United States and the European Union,...
Persistent link: https://www.econbiz.de/10013015192
Persistent link: https://www.econbiz.de/10011696683
The Recovery Fund recently proposed by the EU Commission marks a sea-change in European integration. Yet it will not be enough to meet the challenges Europe faces. There has been much public debate about financing, but little about the sort of concrete projects that the EU should be putting...
Persistent link: https://www.econbiz.de/10012232869
This paper analyzes a maximum price system and a reference price system in a vertical differentiation model with a brand-name drug and a generic. In particular, both instruments are compared with respect to their performance in reducing public expenditure, limiting financial exposure of...
Persistent link: https://www.econbiz.de/10010224844
We suggest an alternative indicator that can lead to price reductions in the public procurement market for goods, i.e., the elasticity of prices to quantities purchased. We apply the analysis to the procurement of medical devices by exploiting a survey from the Italian AntiCorruption Authority....
Persistent link: https://www.econbiz.de/10014472293